All In Biotech

Drug Trial Radar · NCT02196077

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD

Last checked: Nov 19, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Aug 1, 2014

Primary completion

Mar 1, 2015

Study completion Mar 1, 2015

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD. The overall objective is to demonstrate that the combination of budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009) provides benefit on lung function compared with BD MDI in subjects with moderate to severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • BFF MDI 320/9.6 μgDrug

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • BFF MDI 160/9.6 μgDrug

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • BFF MDI 80/9.6 μgDrug

    Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

  • BD MDI 320 μgDrug

    Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)

  • FF MDI 9.6 μgDrug

    Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 AUC0-12 on Day 29Time frame: Day 29

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Pearl Investigative Site

    Rolling Hills Estates, California

  • Pearl Investigative Site

    Clearwater, Florida

  • Pearl Investigative Site

    Panama City, Florida

  • Pearl Investigative Site

    Tampa, Florida

  • Pearl Investigative Site

    Winter Park, Florida

  • Pearl Investigative Site

    Edina, Minnesota

  • Pearl Investigative Site

    Minneapolis, Minnesota

  • Pearl Investigative Site

    Woodbury, Minnesota

  • Pearl Investigative Site

    Saint Charles, Missouri

  • Pearl Investigative Site

    Charlotte, North Carolina

  • Pearl Investigative Site

    Cincinnati, Ohio

  • Pearl Investigative Site

    Columbus, Ohio

  • Pearl Investigative Site

    Dublin, Ohio

  • Pearl Investigative Site

    Medford, Oregon

  • Pearl Investigative Site

    Easley, South Carolina

  • Pearl Investigative Site

    Greenville, South Carolina

  • Pearl Investigative Site

    Spartanburg, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.